Moderate to Severe Alopecia Areata – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Moderate to Severe Alopecia Areata Emerging Therapy and TPP Insights

Thelansis’s “Moderate to Severe Alopecia Areata Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Moderate to Severe Alopecia Areata Overview

Moderate to severe alopecia areata (AA) is an immune-mediated, non-scarring hair-loss disorder in which immune activity disrupts normal hair-follicle cycling. Hair loss may affect the scalp, eyebrows, eyelashes, or body and range from patchy areas to alopecia totalis or universalis. Its course is unpredictable, with spontaneous regrowth in some patients and relapses in others; visible hair loss can substantially affect emotional wellbeing and quality of life. Treatment depends on extent, duration, age, and patient priorities and may include corticosteroids, contact immunotherapy, or other immunomodulators. For extensive disease, oral JAK inhibitors—including baricitinib, ritlecitinib, and deuruxolitinib—are approved in the United States for specific age and severity groups. They can promote regrowth but require safety monitoring, and response may fade after discontinuation. Ongoing research aims to improve durable regrowth, long-term safety, and treatment selection.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)